Articles

San Francisco, CA—The increasing rate of infection with the human papilloma­virus (HPV) in the United States has changed the field of head and neck cancer, or oral cancer, and HPV infection now causes a growing majority (70%-90%) of oropharyngeal squamous-cell carcinomas. As its incidence is rising, so is patients’ curiosity about what sets this cancer apart from other malignancies. Read More ›

• Zejula Now Approved for Late-Line Ovarian Cancer
• Trump Set to Nominate Hahn as FDA Commissioner
• FDA Aims to Improve Breast Implant Guidance

Read More ›

The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer. Read More ›

FDA issues finalized guidelines for use of in vitro diagnostics in oncology drug trials and warnings on vaping; new findings report patients bear more costs when MBC treatment is not concordant with NCCN guidelines. Read More ›

Ovarian cancer is a very difficult disease to diagnose and is the most lethal gynecologic malignancy, being the fifth leading cause of cancer death in women in the United States. A woman’s risk for developing ovarian cancer in her lifetime is approximately 1 in 78, and her lifetime risk for dying of the disease is approximately 1 in 108. The disease was previously thought to begin in the ovaries, but recent research suggests that many ovarian cancers may actually start in the distal end of the fallopian tubes. The following provides key statistics and other helpful information regarding ovarian cancer. Read More ›

Allegheny Health Network (AHN) is a large, integrated healthcare system that provides care to patients throughout western Pennsylvania. As part of this network, the AHN Cancer Institute (AHNCI), offers personalized, high-quality cancer care to patients at >20 locations in and around the Pittsburgh area. The institute uses the latest, most effective anticancer therapies, and through its partnership with Johns Hopkins Kimmel Cancer Center, can offer patients access to clinical trials as well as combined expertise when second opinions are necessary. Read More ›

Chicago, IL—Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. That rate is more than double the 10% that researchers had projected. Read More ›